Get the Daily Brief
Latest Biotech News
Immunology & drug development: Sanofi’s lunsekimig delivers mixed results across respiratory and eczema trials
Sanofi reported mixed Phase 2 data for lunsekimig, a bispecific nanobody targeting TSLP and IL-13, with the asset landing on efficacy in asthma and chronic rhinitis with nasal polyps but missing...
Regulatory and market access: FDA Fast Track for TRI-611 ALK-positive NSCLC molecular glue degrader
The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, positioning the oral, brain-penetrant molecular glue degrader as a potential option after multiple...
M&A: Neurocrine to acquire Soleno for $2.9B to expand Prader-Willi medicine footprint
Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion, paying $53 per share in cash for the Prader-Willi syndrome asset Vykat (diazoxide choline), the companies said. The deal...
Diagnostics & liquid biopsy: UCLA’s methylation blood test aims for multi-disease detection
UCLA researchers published results for MethylScan, a low-cost, single-sample blood test that reads circulating cell-free DNA methylation patterns to detect multiple cancers and liver/organ...
Cancer genetics: Dutch team argues for routine whole-genome sequencing in cancer care
Researchers in the Netherlands are making the case for routine whole-genome sequencing (WGS) for cancer patients, arguing that broad testing yields a high rate of clinically actionable findings...
AI drug discovery: Ligand Pro’s Matcha virtual screening claims 30x speedups
Ligand Pro, founded by Skoltech professors and a Skoltech Ph.D. student, unveiled Matcha, an AI-powered molecular docking model designed to speed virtual drug screening. The company claims Matcha...
Cell therapy & platforms: TriNetX acquisition of Zetta Genomics assets to expand genomics analytics
TriNetX acquired Zetta Genomics assets, aiming to expand its genomics data management and analytics capabilities for healthcare providers and life science researchers. TriNetX’s platform already...
Funding & innovation: Syneron Bio raises $150M Series B for peptide development
Syneron Bio raised a $150 million Series B round to advance peptide therapeutics, according to company reporting, building on its prior $100 million round from the previous year. The company...
FDA accelerates early clinical development in U.S.
The FDA has outlined new budget-driven proposals aimed at shortening the path to first-in-human studies and shifting earlier development momentum back to the U.S., where industry critics say China...
Regulators weigh molecular-glue strategy in ALK-positive NSCLC
The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, signaling regulatory interest in the program as an additional option after resistance to existing ALK...
Sanofi’s lunsekimig delivers in respiratory studies but misses eczema endpoint
Sanofi reported that its bispecific antibody drug lunsekimig (targeting TSLP and IL-13) doubled phase 2 respiratory wins while failing to improve atopic dermatitis severity in a separate phase 2...
Neurocrine to buy Soleno in $2.9B Prader-Willi hyperphagia deal
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, adding Vykat XR (diazoxide choline) to its rare-disease portfolio and boosting its Prader-Willi syndrome exposure....
Amgen pushes injectable Tepezza data as competition nears
Amgen said its injectable version of Tepezza (teprotumumab) cleared a Phase 3 bar in thyroid eye disease, producing comparable efficacy to the infused version in a key study. The company’s updated...
AI moves into clinical protocol design at BMS via Faro Health
Bristol Myers Squibb partnered with Faro Health to use AI-driven structured design for clinical trial protocol development, according to company statements. The multiyear effort is intended to...
Oncology discovery startup Stipple raises $100M for ADC platform
Stipple Bio emerged from stealth with a $100 million Series A financing to advance STP-100, an antibody-drug conjugate targeting an undisclosed tumor antigen, and to scale its Pointillist...
Cell-free methylation test claims low-cost multi-disease screening potential
UCLA researchers reported progress on MethylScan, a low-cost blood test designed to simultaneously detect multiple cancers, liver disorders, and other organ abnormalities using circulating...
Whole-genome sequencing gains traction in routine cancer decision-making
Dutch researchers argued for incorporating whole-genome sequencing into routine cancer care, using real-world analysis to quantify actionable findings beyond standard targeted approaches. In a...
Digital health funding rebounds as investors concentrate bets
Digital health funding rebounded in Q1 2026, reaching $4 billion across 110 deals, according to Rock Health data cited by reporting. The surge was driven primarily by “megadeals,” continuing a...
Regulation and FDA pathway changes for early drug development
The FDA is proposing a new, optional, risk-based expedited Investigational New Drug pathway aimed at reducing time to first-in-human studies for drugs with adequate preclinical data. The plan is...
Biopharma tariffs and industrial policy reshaping drug economics
The Trump administration’s tariff policy for prescription drugs moved from proposal to implementation, imposing a 100% sector tariff on prescription drugs and associated ingredients. Timing begins...